Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
IBA Notice of Full Year 2023 Results and Conference Call | ||
By: GlobeNewswire - 26 Feb 2024 | Back to overview list |
|
FY23 results meeting to take place as a hybrid event on Louvain-la-Neuve, Belgium, 26 February 2024 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the full year 2023 on Thursday, 21 March 2024 at 7am CET. Conference Call Information IBA’s management team will host a hybrid event, including a conference call and webcast conducted in English, to present the half year results, followed by a Q&A session. The conference call will be held on Thursday, 21 March 2024 at 3pm CET / 2pm GMT / 10am ET / 7am PT as a Teams webinar and can be accessed online on this link. If you would like to join by phone only, please dial (Phone conference ID 204 708 166#): Belgium: +32 2 890 97 20 The presentation will be available on IBA’s investor relations website and on https://www.iba-worldwide.com/full-year-results-2023-press-release-and-conference-call shortly before the call. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast. For participants who do not have the Teams application installed, please follow the process described in this link to access the conference. ENDS About IBA IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance. IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com CONTACTS Soumya Chandramouli Olivier Lechien ICR Consilium Attachment |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |